{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T16:07:00Z","timestamp":1789056420921,"version":"build-2803163510"},"reference-count":10,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Advances"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.omta.2026.201828","type":"journal-article","created":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T12:49:15Z","timestamp":1786538955000},"page":"201828","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Amelioration of the neurological phenotype in PKU mouse model emphasizes the potential of base editing for metabolic diseases"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6978-5051","authenticated-orcid":false,"given":"Timo","family":"Keskinen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4806-2377","authenticated-orcid":false,"given":"Mervi E.","family":"Hyv\u00f6nen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.omta.2026.201828_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.omta.2026.201760","article-title":"In vivo adenine base editing rescues brain biochemistry and improves motor deficits in a common phenylketonuria variant","volume":"34","author":"Gautier","year":"2026","journal-title":"Mol. Ther. Adv."},{"key":"10.1016\/j.omta.2026.201828_bib2","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.omta.2026.201828_bib3","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl9238","article-title":"In vivo prime editing of a metabolic liver disease in mice","volume":"14","author":"B\u00f6ck","year":"2022","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.omta.2026.201828_bib4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ymthe.2005.03.025","article-title":"Low therapeutic threshold for hepatocyte replacement in murine phenylketonuria","volume":"12","author":"Hamman","year":"2005","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omta.2026.201828_bib5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/87565641.2016.1243109","article-title":"Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria","volume":"41","author":"Bilder","year":"2016","journal-title":"Dev. Neuropsychol."},{"key":"10.1016\/j.omta.2026.201828_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.omta.2026.201828_bib7","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1038\/s41467-023-39246-2","article-title":"Rapid and definitive treatment of phenylketonuria in variant-humanized mice with corrective editing","volume":"14","author":"Brooks","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.omta.2026.201828_bib8","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1056\/NEJMoa2504747","article-title":"Patient-Specific In Vivo Gene Editing to Treat a Rare Genetic Disease","volume":"392","author":"Musunuru","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.omta.2026.201828_bib9","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ajhg.2020.06.006","article-title":"The Genetic Landscape and Epidemiology of Phenylketonuria","volume":"107","author":"Hillert","year":"2020","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.omta.2026.201828_bib10","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.ajhg.2026.03.018","article-title":"Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platform","volume":"113","author":"Feierman","year":"2026","journal-title":"Am. J. Hum. Genet."}],"container-title":["Molecular Therapy Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S3117387X26001631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T15:14:04Z","timestamp":1789053244000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S3117387X26001631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":10,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S3117387X26001631"],"URL":"https:\/\/doi.org\/10.1016\/j.omta.2026.201828","relation":{},"ISSN":["3117-387X"],"issn-type":[{"value":"3117-387X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amelioration of the neurological phenotype in PKU mouse model emphasizes the potential of base editing for metabolic diseases","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omta.2026.201828","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"201828"}}